Wednesday, June, 19, 2024 10:01:30

The new patent will be valid until 2038 while the firm expects to present ongoing study reports by the second half of 2019.

Zynerba Pharmaceuticals, Inc., the leading developer of innovative pharmaceutically-produced transdermal cannabinoid treatments designed for treating rare and near-rare neuropsychiatric disorders, has recently announced that its cannabidiol (CBD) based Fragile X Syndrome treatment has received a new patent from the U.S. Patent and Trademark Office (USPTO).

According to Zynerba, the patent, valid till 2038, includes claims directed to ways of treating Fragile X Syndrome by managing a therapeutically effective quantity of purified or synthetic cannabidiol. It said that the patent was also a part of enhancing the intellectual property portfolio covering Zynerba’s CBD product segment, ZYN002 Transdermal CBD gel.

Reportedly, the patent issuance follows successful enrollment progresses in CONNECT-FX, a pivotal, randomized, double-blind, multi-national, placebo-controlled study set to evaluate the efficiency and safety of ZYN002 in three 17-year old FXS patients having a full mutation of the FMR1 gene.

As per sources, the study’s primary endpoint was the change from baseline to the end of the treatment period in the FXS Specific Aberrant Behavior Checklist-Community (ABC-C) Social Avoidance subscale. Furthermore, clinical investigative sites are now enrolling patients in the U.S., New Zealand and Australia.

Reports suggest that patients who have completed the double-blind study phase are currently enrolling into the 12-month open-label phase, while the company expects to report its top-line data in the second half of 2019.

For the record, Zynerba Pharmaceuticals is one of the leading producers of pharmaceutically made transdermal cannabinoid therapies and is committed towards improving the lives of patients and their families who are suffering from severe, chronic health conditions such as Autism Spectrum Disorder, Fragile X Syndrome, 22q11.2 Deletion Syndrome, and a heterogeneous group of rare and near-rare epilepsies known as DEE (developmental & epileptic encephalopathies).